MS Therapy Tecfidera Might Exert its Actions by Increasing Specific B-cells

The Effects of Alcohol, Coffee, and Smoking on Multiple Sclerosis
September 22, 2016
Woman says she contracted hepatitis C at dentist 
September 23, 2016
Show all

MS Therapy Tecfidera Might Exert its Actions by Increasing Specific B-cells

The medication Tecfidera increases numbers of regulatory B-cells.

While treatment of relapsing-remitting multiple sclerosis (RRMS) with Tecfidera (dimethyl fumarate) keeps relapse rates low, the details of immune changes induced by the drug are still evading scientists. A new study reported that the treatment increases the number of regulatory B-cells (Bregs), presenting a potential marker of treatment response.

The study “Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets“ was published in the journalNeuroimmunology & Neuroinflammation.

Recent studies have shown that Tecfidera decreased certain immune cells, of both B-, and T-cell type in MS patients. Studies have also indicated that this class of drugs affects the signaling through IL-10, a key regulator of immune responses. This anti-inflammatory cytokine is most often released by regulatory B-, and T-cells (Tregs).

Read Full Article: MS Therapy Tecfidera Might Exert its Actions by Increasing Specific B-cells – Multiple Sclerosis News Today

Read Full Article: MS Therapy Tecfidera Might Exert its Actions by Increasing Specific B-cells – Multiple Sclerosis News Today

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.